Several studies revealed the high specificity of p53 autoantibodies in advanced CRC (89-100%), whereas its sensitivity varies from 8.8% to 46.3%, which significantly reduces its diagnostic ability of the disease (138, 143, 153–156). This evidence concerns the gene TP53 and colorectal carcinoma.